Bioretec Ltd. announced that Timo Lehtonen, Bioretec's CEO since 2019, will transfer to the position of Chief Technology Officer (CTO) and continue to lead the development of Bioretec's future product pipeline.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2.87 EUR | +4.36% | +2.50% | +19.58% |
Jun. 19 | Bioretec Ltd. Reports Successful Clinical Outcomes from U.S. Controlled Launch of RemeOs Trauma Screw | CI |
May. 21 | Medical Device Company Bioretec Names New CEO | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+19.58% | 62.54M | |
+75.69% | 12.57B | |
+11.24% | 6.92B | |
-30.25% | 6.8B | |
+11.54% | 5.32B | |
-20.60% | 4.63B | |
+10.66% | 3.94B | |
-22.90% | 3.86B | |
-28.90% | 2.68B | |
+28.43% | 2.06B |
- Stock Market
- Equities
- BRETEC Stock
- News Bioretec Oy
- Bioretec Ltd. Announces Transfer of Timo Lehtonen from CEO to Chief Technology Officer